[Pre-print, not peer-reviewed]<\/i> Extending the interval between doses of the Moderna vaccine from 4 weeks to 9-12 weeks could prevent additional infections, hospitalizations, and deaths according to an agent-based model. However, there was no clear advantage for delaying the second dose of the Pfizer-BioNTech vaccines beyond the standard 3-week interval. This is largely attributable to the differences in efficacy used for the first dose of each vaccine (52% for the Pfizer-BioNTech versus 80% for the Moderna vaccine). The authors note uncertainty about how quickly immunity wanes following vaccination, and developed scenarios with different assumptions for this parameter.<\/p>\n
Moghadas et al. (Jan 29, 2021). Evaluation of COVID-19 vaccination strategies with a delayed second dose. Pre-print downloaded Jan 29 from <\/i>https:\/\/doi.org\/10.1101\/2021.01.27.21250619<\/a>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":" [Pre-print, not peer-reviewed] Extending the interval between doses of the Moderna vaccine from 4 weeks to 9-12 weeks could prevent additional infections, hospitalizations, and deaths according to an agent-based model. However, there was no clear advantage for delaying the second dose of the Pfizer-BioNTech vaccines beyond the standard 3-week interval. This is largely attributable to…<\/p>\n